Glenmark launches sunitinib generic – priced 96% lower than innovator brand

17 February 2021

India’s Glenmark Pharmaceuticals (BSE: 532296) has launched Sutib, its generic version of sunitinib oral capsules to treat kidney cancer in India. The company's shares closed up nearly 3% at 505.05 rupees following the announcement today.

The drug is launched at a MRP that is around 96% lower than the MRP compared to the innovator brand, US pharma giant Pfizer’s (NYSE: PFE) Sutent, priced at 7,000 rupees ($96.22) for 50mg), 3,600 rupees (25mg) and 1,840 rupees (12.5mg) per month.

Sutent, which is globally approved including by the US Food and Drug Administration, is facing patent expiry, as a result of which worldwide sales of the drug in 2020 declined 12% to $819 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK